scholarly journals Studying the expression rate and methylation of Reprimo gene in the blood of patients suffering from gastric cancer

2018 ◽  
Vol 28 (2) ◽  
Author(s):  
Amin Abbasi ◽  
Sahar Heydari
Keyword(s):  
Gastric Cancer ◽  
Early Diagnosis ◽  
Cancer Patients ◽  
Methylation Status ◽  
Blood Samples ◽  
Specific Pcr ◽  
Expression Rate ◽  
And Performance ◽  
Gastric Cancer Patients ◽  
Gene Age

As gastric cancer has no exclusive signals in its initial phases, it is usually diagnosed in advanced phases. Although many researches have been conducted on methylation and diagnosis of cancer’s markers, the methylation and expression of Reprimo gene and its correlation with gastric cancer has not been thoroughly studied. Methylation of Reprimo promoter is a repetitive procedure exclusive to cancer which nullifies its expression and performance. The present research seeks to study the expression and methylation of Reprimo among people suffering with gastric cancer so that it may be used as a biomarker for early diagnosis. Fifty blood samples taken from healthy people (normal samples) and 50 blood samples obtained from gastric cancer patients were analyzed using Real-Time PCR. The methylation status of the promoter of Reprimo was studied using Methylation Specific PCR technique in normal samples and in gastric cancer Iranian patients. We observed reduction in expression rate of Reprimo in the blood samples of patients suffering with gastric cancer in comparison to normal blood samples. A significant correlation was also observed between the expression rate of this gene, age and methylation of its promoter among patients suffering with gastric cancer and various analysis points to a correlation between reduced expressions of Reprimo gene in gastric cancer patients. In conclusion, reduced expression of Reprimo gene and greater levels of methylation of its promoter seems to be promising biomarkers for early diagnosis of gastric cancer.

scholarly journals Methylation ofDLEC1Promoter Is a Predictor for Recurrence in Chinese Patients with Gastric Cancer

2014 ◽  
Vol 2014 ◽  
pp. 1-6 ◽  
Author(s):  
Xiaobing Ye ◽  
Gang Feng ◽  
Nanlin Jiao ◽  
Chun Pu ◽  
Guohai Zhao ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Esophageal Cancer ◽  
Cancer Patients ◽  
Promoter Methylation ◽  
Chinese Patients ◽  
Promoter Regions ◽  
Specific Pcr ◽  
Gastric Cancer Patients ◽  
Clinicopathological Variables ◽  
Valuable Predictor

Purpose. To investigate promoter methylation in the deleted in lung and esophageal cancer 1 (DLEC1) gene in Chinese patients with gastric cancer.Methods. A total of 227 patients with gastric cancer were enrolled. The methylations of the promoter regions ofDLEC1and ACTB were determined using quantitative methylation-specific PCR. TheDLEC1methylation was compared to the clinicopathological variables of gastric cancer.Results.DLEC1methylation was not associated with the clinicopathological variables of gastric cancer. Patients withDLEC1-hypermethylated gastric cancer had significantly higher recurrence rate than those withDLEC1-hypomethylated gastric cancer (P=0.025;hazard ratio=2.43).Conclusions. Methylation of DELC1 promoter may be a valuable predictor for recurrence in Chinese patients with gastric cancer.

DNA methylation status is inversely correlated with green tea intake and physical activity in gastric cancer patients

2008 ◽  
Vol 124 (11) ◽  
pp. 2677-2682 ◽  
Author(s):  
Yasuhito Yuasa ◽  
Hiromi Nagasaki ◽  
Yoshimitsu Akiyama ◽  
Yutaka Hashimoto ◽  
Touichirou Takizawa ◽  
...  
Keyword(s):  
Physical Activity ◽  
Gastric Cancer ◽  
Dna Methylation ◽  
Cancer Patients ◽  
Green Tea ◽  
Methylation Status ◽  
Gastric Cancer Patients

Methylation status of IGF2 DMR and LINE1 in leukocyte DNA provides distinct clinicopathological features of gastric cancer patients

2017 ◽  
Vol 18 (2) ◽  
pp. 215-220 ◽  
Author(s):  
Tomomitsu Tahara ◽  
Sayumi Tahara ◽  
Noriyuki Horiguchi ◽  
Tomohiko Kawamura ◽  
Masaaki Okubo ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Cancer Patients ◽  
Methylation Status ◽  
Clinicopathological Features ◽  
Igf2 Dmr ◽  
Gastric Cancer Patients

scholarly journals Expression Rate and PAX5 Gene Methylation in the Blood of People Suffering from Gastric Cancer

2018 ◽  
Vol 6 (9) ◽  
pp. 1571-1576 ◽  
Author(s):  
Mozhdeh Khajeh Haghverdi ◽  
Elham Moslemi
Keyword(s):  
Gastric Cancer ◽  
Promoter Methylation ◽  
Methylation Status ◽  
Gene Promoter ◽  
Gene Promoters ◽  
Health Issues ◽  
Blood Samples ◽  
Important Health ◽  
Expression Rate ◽  
Pax5 Gene

BACKGROUND: Gastric cancer is one of the most important health issues in the world. Considering the lack of plenty of pre-awarenesses, the survival of gastric cancer is still quite disappointing. Methylation of PAX5 gene promoter is observed in most cancer cells of a human. A study has shown that PAX5 is a new tumoral suppressor in gastric cancer and methylation of the PAX5 promoter is associated with the survival rate of gastric cancer. AIM: The present research seeks to study the expression rate and methylation of the PAX5 gene in the blood of patients who have gastric cancer to be used as a biomarker in this type of cancer. MATERIAL AND METHODS: Real-time PCR technique was used to assess expression of PAX5 gene, while the methylation status of PAX5 gene promoter in the blood samples of people who have gastric cancer versus blood samples obtained from normal Iranian population was studied using MS PCR technique. RESULTS: The final results pointed to the fact that expression of PAX5 in blood samples obtained from those who have gastric cancer is much less than what is observed in normal blood samples. A significant correlation was also observed between expression of this gene and age and promoter methylation rate. The results of methylation also indicated that 28% of PAX5 gene promoters among patients were methylated, while all normal samples were non-methylated. CONCLUSION: Studying the decrease observed in PAX5 gene expression and the rise in promoter methylation can be utilised as a biomarker to enhance pre-awareness of gastric cancer.

Association of extensive delayed overmethylation influenced by advanced atrophy with risk for gastric cancer.

2015 ◽  
Vol 33 (3_suppl) ◽  
pp. 13-13
Author(s):  
Jung Hwan Oh ◽  
Sung Hoon Jung ◽  
DaeYoung Cheung ◽  
Mun Gan Rhyu ◽  
Seung Jin Hong
Keyword(s):  
Gastric Cancer ◽  
Cancer Patients ◽  
Cpg Island ◽  
The Body ◽  
Body Site ◽  
Mucosal Atrophy ◽  
Specific Pcr ◽  
Gastric Cancer Patients ◽  
Cell Phenotypes ◽  
Negative Controls

13 Background: Helicobacter pylori (HP) infection facilitates overmethylation of CpG-island genes, which can be delayed by advanced mucosal atrophy. Delayed overmethylation results in unstable cell phenotypes responsible for gastric cancer. To delineate cancer risk period, the overmethylation period from HP infection to severe atrophy was traced in the gastric cancer and dysplasia. Methods: A pair of normal-appearing mucosal specimens was obtained from the antrum and body of 110 HP-positive and 95 HP-negative controls, 99 cancer patients, and 118 dysplasia patients. Gastric mucosal atrophy was assessed using the endoscopic atrophic border score. Eight CpG-island genes adjacent to Alu (CDH1, ARRDC4, PPARG, TRAPPC2L) and LTR retroelements (MMP2, CDKN2A, RUNX2, RUNX3) and the TFF3 gene lacking CpG island were chosen. The methylation-variable sites in gene-control regions were analyzed using radioisotope-labeling methylation-specific PCR. Results: The antrum-specific TFF3 gene on the antrum tended to be overmethylated earlier than Alu-type CpG-island genes on the body in the HP-positive controls with mild mucosal atrophy (mean age; 50 years vs. 52 years). In moderate atrophic cases, the antrum-site TFF3 overmethylation was delayed four years compared with the whole cases (58 years vs. 54 years) and the Alu-type overmethylation on the body was early detected (49 years). Gastric cancer patients with moderate atrophy induced a late overmethylation on both the antrum and body site (56 and 58 years) and increased LTR-type slow overmethylation (OD, 5.3; 95% CI, 2.0-14.1). Dysplasia patients (65 years) older than gastric cancer sustained an early Alu-type overmethylation on the body site. Conclusions: Moderate atrophy of the gastric mucosa can delay overmethylation of CpG-island genes, which leads to unstable cancer period and subsequent stable dysplasia period.

scholarly journals Prognostic Role of RASSF1A, SOX17 and Wif-1 Promoter Methylation Status in Cell-Free DNA of Advanced Gastric Cancer Patients

2021 ◽  
Vol 20 ◽  
pp. 153303382097327
Author(s):  
Evangelos I. Karamitrousis ◽  
Ioanna Balgkouranidou ◽  
Nikolaos Xenidis ◽  
Kyriakos Amarantidis ◽  
Eirini Biziota ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Overall Survival ◽  
Advanced Gastric Cancer ◽  
Cancer Patients ◽  
Methylation Status ◽  
Progression Free Survival ◽  
Cell Free Dna ◽  
Free Survival ◽  
Free Dna ◽  
Gastric Cancer Patients

Epigenetic modification of several genes is a key component in the development of gastric cancer. The methylation status of RASSF1A, SOX17 and Wif-1 genes was evaluated in the cell free circulating DNA of 70 patients with advanced gastric cancer, using methylation-specific PCR. Patients with higher cell-free DNA concentration seem to have lower PFS, than patients with lower cell-free DNA concentration (p = 0.001). RASSF1A was the tumor suppressor gene, most frequently methylated in metastatic gastric cancer patients, followed by SOX17 and Wif-1 (74.3%, 60.0% and 47.1%, respectively). Patients having the SOX17 promoter methylated, had lower progression free survival and overall survival, than unmethylated ones (p < 0.001). Patients having the Wif-1 promoter methylated, had lower progression free survival and overall survival, than unmethylated ones (p = 0.001). Patients having the RASSF1A promoter methylated, had lower progression free survival and overall survival, than unmethylated ones (p = 0.004). Promoter methylation of the examined genes was significantly associated with a decrease in progression free survival and overall survival, comparing to that of patients without methylation. Simultaneous methylation of the above genes was associated with even worse progression free survival and overall survival. The methylation of RASSF1A, SOX-17 and Wif-1 and genes, is a frequent epigenetic event in patients with advanced gastric cancer.

Sign in / Sign up

Export Citation Format

Share Document